Unichem Lab Gets USFDA Nod For Pain Management Drug
A worker washes the test slide of an agglutination kit inside a medical laboratory at a Sudar Hospitals clinic in Chennai, India. (Photographer: Dhiraj Singh/Bloomberg)

Unichem Lab Gets USFDA Nod For Pain Management Drug

Listen to Article

Drug firm Unichem Laboratories Ltd. has received approval from the U.S. health regulator to market pain management drug Tramadol Hydrochloride tablets.

The company has received abbreviated new drug application approval from the U.S. Food and Drug Administration for Tramadol Hydrochloride tablets USP, in the strength 50 mg, Unichem Laboratories said in a regulatory filing on Tuesday.

The approved product is a generic version of Ultram tablets, 50 mg, of Janssen Pharmaceuticals, Inc. Tramadol Hydrochloride tablets are indicated for use in adults for the management of pain severe enough to require an opioid analgesic, and for which alternative treatments are inadequate.

Unichem said the product will be commercialised from its Ghaziabad, Uttar Pradesh, plant.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.